FGF21 and metabolic dysfunction-associated steatohepatitis: Pegbelfermin is a pegylated analog of FGF21 and was used for NASH patients during the phase IIa trial, where it showed a meaningful reduction in hepatic fat percentage at the dose of 10 mg/day.